about
Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics.Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice.Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.No Clinically Relevant Drug-Drug Interactions Between Methadone or Buprenorphine/Naloxone and Anti-Viral Combination Glecaprevir and Pibrentasvir.Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in HCV-Negative Subjects.Safety, tolerability, and pharmacodynamics of an anti-interleukin-1α/β dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study.Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study.Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV InfectionPharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT-981 Against IL-1α and IL-1β in Healthy Subjects and Patients With Osteoarthritis of the Knee
P50
Q34099771-BEA8FD51-DF36-45ED-9CF6-F921E35B6B89Q34283156-39B639D9-4E66-4421-BD1B-FB3D4F0A92E3Q36912731-658D2012-1EEF-4F17-B16A-2CBE245DC5BCQ37428963-DE22D70E-B23F-4A85-B930-8BB9F69D0D73Q37686530-03944E99-F9B1-43F8-BCB5-35F99D110E2DQ39600375-D3E73228-A346-436B-B8F8-F4DD1AE75B6BQ40083240-E87E149C-AEA7-452B-8B70-7571C752F78FQ41918943-6CA9C134-A264-43D2-997F-15FF07795BA7Q47562694-D69A5256-4D6C-47E2-BD5D-3DC89365436CQ47720673-4FFAF404-A272-4937-83DB-50164867F3DCQ52642614-F7AAA317-B48E-4F36-92E1-C8A387AF28CCQ59356838-A6227AD3-E1F4-4C80-8DA7-7930C4064BE8Q89377853-408576D1-82ED-4547-890E-5CD0CD104539
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Matthew P Kosloski
@ast
Matthew P Kosloski
@en
Matthew P Kosloski
@es
Matthew P Kosloski
@nl
type
label
Matthew P Kosloski
@ast
Matthew P Kosloski
@en
Matthew P Kosloski
@es
Matthew P Kosloski
@nl
prefLabel
Matthew P Kosloski
@ast
Matthew P Kosloski
@en
Matthew P Kosloski
@es
Matthew P Kosloski
@nl
P108
P31
P496
0000-0002-6642-2439